Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels

AIDS. 2005 Nov 18;19(17):2031-3. doi: 10.1097/01.aids.0000194130.05264.83.

Abstract

Despite its wide use, the renal tubular toxicity of tenofovir has not been fully evaluated. Twelve weeks after initiating a tenofovir-containing HAART regimen, a high urine-beta 2 microglobulin level was observed in 12 out of 17 patients, the percentage of tubular reabsorption of phosphate decreased from 96.0 to 91.1% and alkaline phosphatase increased from 294 to 365 U/l, whereas serum creatinine and phosphorus remained largely unchanged. Patients with the above findings should be monitored carefully for renal tubular toxicity.

MeSH terms

  • Absorption
  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adult
  • Alkaline Phosphatase / pharmacokinetics
  • Antiretroviral Therapy, Highly Active / methods
  • Creatinine / blood
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Infections / urine
  • HIV-1*
  • Humans
  • Kidney Tubules / drug effects*
  • Kidney Tubules / metabolism
  • Middle Aged
  • Organophosphonates / adverse effects*
  • Phosphates / pharmacokinetics
  • Phosphorus / blood
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Tenofovir
  • Uric Acid / blood
  • beta 2-Microglobulin / urine*

Substances

  • Organophosphonates
  • Phosphates
  • Reverse Transcriptase Inhibitors
  • beta 2-Microglobulin
  • Uric Acid
  • Phosphorus
  • Tenofovir
  • Creatinine
  • Alkaline Phosphatase
  • Adenine